Christopher Bailey

Christopher Bailey is an accomplished medicinal chemist with extensive experience in drug discovery and development. Currently serving as Associate Principal Scientist III at Recursion since April 2022, Christopher has previously held key roles at Pliant Therapeutics, where significant contributions included the discovery of PLN-1474, a clinical candidate for PhI trials. At Theravance Biopharma, Christopher focused on lung-restrictive therapies, designing and synthesizing a range of compounds to advance asthma treatments. Early career roles included positions at Genentech, UC Santa Cruz, and various analytical and production labs. Christopher earned a Ph.D. in Chemistry from the University of California, Santa Cruz, and a B.Sc. in Biochemistry from California Polytechnic State University-San Luis Obispo.